15:02 , Dec 22, 2017 |  BC Week In Review  |  Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
07:01 , Dec 21, 2017 |  BC Extra  |  Financial News

Aura raises $30M series C

Aura Biosciences Inc. (Cambridge, Mass.) raised $30 million in a series C round led by new investors Lundbeckfonden Ventures and Arix Bioscience plc. Existing investors also participated, including Advent Life Sciences, Chiesi Ventures, Ysios Capital,...
18:57 , Apr 26, 2017 |  BC Week In Review  |  Clinical News

AU-011: Ph Ib started

Aura began an open-label, U.S. Phase Ib trial to evaluate single injections of 2 dose levels of intravitreal AU-011 in up to 12 patients. Aura Biosciences Inc. , Cambridge, Mass.  Product: AU-011   Business: Cancer ...